Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has been drawing attention after a period of solid share price gains. This is prompting investors to reassess how its current ...

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...

AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use ...

If you are wondering whether AstraZeneca shares still offer fair value after a strong run, or if you might be paying too much ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration - though much of what it is ...

AstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. The British pharma—which sells Lynparza as a prostate cancer treatment and is also testing its Truqap in ...

AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said in a first look at the data from a key phase 3 win. Baxdrostat has a ...

Astrazeneca (AZN) closed at $94.01 in the latest trading session, marking a -1.21% move from the prior day. This move lagged ...